Table 2.

c-MYC/BCL2 Protein co-Expression and Outcome of DLBCL Treated with Chemotherapy

Clinical characteristics	c-MYC/BCL2 co-expression			Overall
	Yes	No	P value	n (%)	OS	EFS
	n (%)	n (%)			P value	P value
Age groups
Age < 60	19 (54.3)	18 (50)	0.718	52 (53.6)	0.125	0.122
Age ≥ 60	16 (45.7)	18 (50)		45 (47.4)
Ethnicity
Malay	18 (51.4)	18 (50)	0.647	53 (54.6)	0.961	0.758
Chinese	14 (40.0)	14 (38.9)		33 (34.0)
Indian	2 (5.7)	4 (11.1)		9 (9.3)
Other	1 (2.9)	0 (0)		2 (2.1)
Gender
Males	16 (45.7)	19 (52.8)	0.552	52 (53.6)	0.088	0.111
Females	19 (54.3)	17 (47.2)		45 (46.4)
Staging
I-II	12 (34.3)	16 (44.4)	0.381	40 (41.2)	0.007	0.008
III-IV	23 (65.7)	20 (55.6)		57 (58.8)
B Symptoms
No	9 (25.7)	11 (30.6)	0.65	34 (35.1)	<0.001	<0.001
Yes	26 (74.3)	25 (69.4)		63 (64.9)
Serum LDH
Normal	8 (22.9)	10 (27.8)	0.634	29 (29.9)	<0.001	<0.001
Elevated	27 (77.1)	26 (72.2)		68 (70.1)
IPI category
Low risk (score 0-2)	15 (42.9)	20 (55.6)	0.285	58 (59.8)	<0.001	<0.001
High risk (score 3-5)	20 (57.1)	16 (44.4)		39 (40.2)
Cell of origin
GCB	7 (20)	15 (41.7)	0.048	25 (31.6)	0.549	0.705
Non-GCB	28 (80)	21 (58.3)		54 (68.4)
c-MYC/BCL2 co-expression
No	-	-	-	36 (50.7)	0.038	0.049
Yes	-	-		35 (49.3)

LDH, lactate dehydrogenase; IPI, International Prognostic Index; GCB, germinal center B-cell; OS, overall survival; EFS, event free survival.